Companion Diagnostics Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis

The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016-2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic (CDx) test products.
The U.S. FDA lays emphasis on regulatory clearance of companion diagnostics, in its recent draft guidance in 2016, before approving any oncology product that requires and in-vitro diagnostic (IVD) companion diagnostic device for tis safe and effective use. Therefore, drug developers and diagnostic test manufacturers need to work in close collaborations in order to avoid any regulatory bottlenecks. AstraZeneca plc struck a deal with Abbott Laboratories, Inc. in 2015 to develop a companion diagnostic test for tralokinumab, used for treating severe asthma. If successful, this would be the first companion diagnostic test developed for asthma. Moreover, AstraZeneca expects half of its drug launches to include companion diagnostic by 2020. This is a major factor implying the importance of companion diagnostics in treating chronic diseases.
Simultaneous development of a companion diagnostic test and the drug candidate has its own set of pros and cons that act as a trade-off for pharmaceutical companies. Developing companion diagnostic risks holding up of effective drug therapies, and making major investments on companion diagnostics early is a perceived risk, as many drug candidates fail to make it to the market. However, personalized medicine is the emerging therapeutic approach for cancer and other chronic therapies. Thus, developing a companion diagnostic for faster FDA approval makes it imperative for researchers to invest in the development of CDx tests.
Agilent technologies, Inc. announced the extended use of its CE approved Dako PD-L1 IHC 22C3 pharmDx in January 2017, in determining PD-L1 expression status in patients with metastatic non-small cell lung cancer (NSCLC). This device helps determine the expression level of PD-L1 in both untreated and previously treated metastatic NSCLC patients with KEYTRUDA (pembrolizumab), a first-line treatment drug for metastatic NSCLC. With this approval, patients with metastatic NSCLC and in the second-line or later treatment settings can also be identified for treatment with KEYTRUDA.
Invivoscribe Technologies Inc., has companion diagnostics development deal with Novartis AG and Astellas Pharma Inc. Invivoscribe Technologies Inc. has developed a companion diagnostic test for FLT3, a biomarker for the stratification and prognosis of acute myeloid leukemia (AML). This CDx is under the U.S. FDA review for its use with PKC412 (midostaurin) an investigational drug for adults with newly-diagnosed AML and who are FLT3 mutation-positive. If granted approval the LeukoStrat CDx FLT3 Mutation Assay would be the first CDx for AML.
Approval of the drug and CDx test at the same time is difficult. However, the endeavor to develop effective targeted therapies at low cost and faster time to market would encourage more drug developers to conduct clinical trials with diagnostics as part of the inclusion/exclusion criteria.
Key takeaways of the global companion diagnostics market:
• The global companion diagnostics market is expected to expand at a CAGR of 12% during the forecast period (2016-2024). Improved clinical outcomes, reduced total research cost and faster time to market are some of the major factors driving collaborations and CDx development globally
• The breast cancer application in the global companion diagnostics market was estimated to be the largest in 2015 and is expected to dominate the companion diagnostics market throughout the forecast period in terms of value. This is owing to high number of approved brands with CDx tests, driving adoption of these products in treatment of breast cancer.
• In terms of technology, the gene sequencing method segment is expected to expand at a CAGR of 12.6% during the forecast period. Growth of the segment is mainly attributed to increasing focus on identification of genetic mutations that can help in precise identification of the treatment approach for cancer therapies.
• The global companion diagnostics market is characterized by strategic research and development collaborations among the drug and diagnostic test developers. According to the Wildwood Ventures Ltd., the number of global deal in companion diagnostics market has increased from 13 in 2007 to 66 in 2013.
• Some of the major players in the global companion diagnostics market include Abbott Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, GE Healthcare, Qiagen N.V., Roche Diagnostics, Biomérieux, Myriad Genetics, Inc., bioMérieux SA, and Siemens Healthcare.

Wireless Monitoring System Market - Size, Share, Outlook, and Forecast till 2026

Published Date : Jun 2018

Wireless monitoring system uses Wi-Fi technology, which covers large areas through the use of repeaters and boosters making it ideal solution for large installations. Wireless systems have range of...

UAV Propellers Market - Size, Share, Outlook, and Forecast till 2026

Published Date : Jun 2018

Unmanned Aerial Vehicles (UAV) commonly known as drone is an aircraft without pilot on board. UAVs can be remote controlled or they are designed to fly autonomously based on pre-programmed flight p...

Tire Bead Wire Market - Size, Share, Outlook, and Forecast till 2026

Published Date : Jun 2018

Tire bead wire is a drawn steel wire, which is manufactured from quality wire rods with high carbon content. The surface of the bead wire is coated with copper or bronze, which ensures proper adhes...

Starter Feed Market - Size, Share, Outlook, and Forecast till 2026

Published Date : Jun 2018

Starter feed is majorly mixture of two or more ingredients, which is prepared commercially for livestock animals. It contains highly digestible protein products, probiotics, acidifiers, enzymes and...

Spinel Earrings Market - Size, Share, Outlook, and Forecast till 2026

Published Date : Jun 2018

Spinel gemstone is a transparent to opaque gem, which is found in varied ranges of colors, including ruby reds, brick reds, and orang reds. Spinel are also available in blue, and look similar to sapphires, however, considered extremely rare. These gems also occurs in ...

Spherical Alumina Adsorbent Market - Size, Share, Outlook, and Forecast till 2026

Published Date : Jun 2018

Spherical alumina adsorbent is a dry, granular chemical substance produced by de-hydroxylation of aluminum hydroxide. It is primarily used for the filtration of water to remove harmful fluorides an...

Rebreathers Market - Size, Share, Outlook, and Forecast till 2026

Published Date : Jun 2018

A rebreather is an aqualung that partially purifies diver's exhaled breath using carbon dioxide, mixed with more oxygen, which can be breathed again by the diver. Absorption of the carbon dioxide f...

Propyl Chloroformate Market - Size, Share, Outlook, and Forecast till 2026

Published Date : Jun 2018

Chloroformates are esters of chloroformic acid and propyl chloroformates are one of those esters, which is a colorless liquid with pungent odor. It is widely used as reagents in organic chemistry a...

Procalcitonin Antibody Market - Size, Share, Outlook, and Forecast till 2026

Published Date : Jun 2018

Procalcitonin (PCT) is a peptide precursor of 116 amino acids produced by parafollicular cells of the thyroid and neuroendocrine cells of lungs and intestine. It is used for synthesis of hormone ca...

Prismatic LiFePO4 Battery Market - Size, Share, Outlook, and Forecast till 2026

Published Date : Jun 2018

Prismatic LiFePO4 battery is a type of lithium-ion battery that make optimal use of space by using ...

 

Select Licence :

  • Single User : $4500
  • Multiple User : $7000
  • Corporate User : $10000

Happy To Assist You

Assist you at Worldwide Market Reports

We will be happy to help you find what you need. Please call us or write to us:

Worldwide Market Reports Benefits

Custom Research Solution

Talk to our research consultant to design an exclusive report as per your research needs.

Customer Fulfilment

We aim to fulfil client's research demands with tailored research solutions.

Quick Turnaround Time Reports

We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

360-degree Approach

We cover each industry from supply and demand side with an aim to provide a most holistic research study.